Oxford, UK based Oxford BioTherapeutics has steadily been rolling out new partnerships, most recently with Bristol, Roche, and GSK, for its antibody and target discovery work

1 day ago
1 min read

CEO Christian Rohlff describes the types of programs Oxford will be collaborating with these companies on, and discussed why the company has prioritized partnerships over an internal pipeline lately. Plus, details on a unique database the company has derived that could lead to even further programs and deals.

Recent Posts

See All

Oxford, UK based Sitryx has been busy lately with a deal announced with Boehringer Ingelheim, and its lead program targeting PKM2 in the clinic for atopic dermatitis

Oxford, UK based Brainomix has developed an AI based platform that is designed to help hospitals diagnose the existence and severity of strokes from scans quickly as every minute counts

Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads

Oxford, UK based Oxford BioTherapeutics has steadily been rolling out new partnerships, most recently with Bristol, Roche, and GSK, for its antibody and target discovery work

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight